The FDA approved insulin-aspart-szjj (Merilog) as the first rapid-acting insulin biosimilar product to treat adults and ...

Crispr Therapeutics (CRSP) has disclosed a new risk, in the Innovation / R&D category. Crispr Therapeutics faces a significant business risk due ...

In patent damages calculations, an expert generally faces the task of comparing the actual outcome (with infringement) to the ...

Biosimilars have the potential to reduce health care costs and expand patient access, but economic and policy barriers affect adoption, explored James D. Chambers, PhD, MPharm, MSc, associate ...

January started the year off strong, with several business updates, long-term clinical trial results on multiple biosimilars, ...

The FDA has approved a third biosimilar for tocilizumab, called Avtozma, the second such biosimilar to be available in both intravenous and subcutaneous formulations, according to a press release.

Tocilizumab-anoh is the seventh biosimilar by Celltrion to receive FDA approval, enhancing their treatment portfolio. Avtozma, the third biosimilar to Actemra, has received FDA approval for ...

On January 29, 2025, the Federal Circuit issued paired decisions addressing Samsung Bioepis’s (“SB”) and Formycon AG’s (“Formycon”) appeals ...

Galenica Group sales once again performed very positively in 2024, with growth of 4.7% to CHF 3,922 million. As a result, Galenica outperformed the entire pharmaceutical market in terms of growth ...

Pharmacists reminded of biosimilar substitution requirements Pharmacists are being advised to pay attention when selecting Pharmaceutical Benefits Scheme (PBS) codes when substituting biosimilar ...

Sigma’s merger with Chemist Warehouse will create multimillionaires, proxy advisory firm says Chemist Warehouse shareholders could find themselves on the Australian Financial Review’s Rich List, if ...

MANILA, Philippines — Sen. Risa Hontiveros filed a substitute bill for the "Prevention of Adolescent Pregnancy Act" following the withdrawal of signatures by several senators and concerns raised ...